PT  - JOURNAL ARTICLE
AU  - Cedric Van Holsbeke
AU  - Aukje Bos
AU  - Wim Vos
AU  - Jan De Backer
AU  - Hettie Janssens
AU  - Harm Tiddens
TI  - Airway surface liquid concentrations of aztreonam lysine for inhalation in children with cystic fibrosis: A modeling study
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P2114
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P2114.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P2114.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - IntroductionThe mechanics of inhaled antibiotics in obstructed airways are not well known. It is possible that local areas with concentration below the minimal inhibitory concentration (10xMIC90, 128µg/ml for P. Aeruginosa) exist, causing undertreated parts of the lung. To optimize inhaled therapy, knowledge about antibiotic concentrations throughout the lung should be known. Local deposition characteristics of inhaled Aztreonam lysine (AZLI) were simulated using Functional Respiratory Imaging.MethodsAirways and lungs were segmented from a retrospective dataset of 40 in- and expiratory CT-scans of children with cystic fibrosis (CF) between 5 and 17 years. FRI simulations were performed that simulated the nebulisation of 75mg AZLI through PARI eFlow® with minimal/median/maximal reported aerodynamic diameters (MMAD) and different thicknesses of airway surface liquid (ASL). Figure 1 shows local concentrations in the central airways and lung.ResultsIn Figure 2, it is shown how many lobes are being undertreated.ConclusionParts of the CF-lung receive concentrations < 10xMIC90 with inhaled antibiotics, such as AZLI.